Underutilisation of breast cancer prevention medication in Australia

Breast. 2021 Dec:60:35-37. doi: 10.1016/j.breast.2021.08.013. Epub 2021 Aug 23.

Abstract

Increased implementation of proven prevention strategies is required to combat rising breast cancer incidence. We assessed use of risk reducing medication (RRMed) by Australian women at elevated breast cancer risk. Only 2.4% had ever used RRMed. Higher breast cancer risk was statistically significantly associated with use of RRMed (OR 1.82, 95%CI: 1.08-3.07, p = 0.02 for ≥30% lifetime risk compared with 16%-29% lifetime risk), but parity, education level and family history of breast cancer were not. Breast cancer prevention medications are underutilised. Efforts are needed to incorporate breast cancer risk assessment and risk management discussions into routine health assessments for women.

Keywords: Breast cancer; Chemoprevention; Prevention; Risk; Tamoxifen.

MeSH terms

  • Australia / epidemiology
  • Breast Neoplasms* / epidemiology
  • Breast Neoplasms* / prevention & control
  • Female
  • Humans
  • Risk Assessment
  • Risk Factors
  • Tamoxifen*

Substances

  • Tamoxifen